International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

Vinpocetine inhibits the proliferation and induces apoptosis in human colon cancer cells

  • Kim, Mi-Kyoung (Department of Oral Physiology, Pusan National University School of Dentistry) ;
  • Park, Hyun-Joo (Department of Oral Physiology, Pusan National University School of Dentistry) ;
  • Kim, Yeon (Department of Oral Physiology, Pusan National University School of Dentistry) ;
  • Kim, Yong-Il (Department of Orthodontics, Pusan National University School of Dentistry) ;
  • Bae, Soo-Kyung (Department of Dental Pharmacology, Pusan National University School of Dentistry) ;
  • Kim, Hyung Joon (Department of Oral Physiology, Pusan National University School of Dentistry) ;
  • Bae, Moon-Kyoung (Department of Oral Physiology, Pusan National University School of Dentistry)
  • Received : 2020.12.30
  • Accepted : 2021.01.06
  • Published : 2021.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Vinpocetine induces anti-inflammatory effects in various inflammatory diseases via the inhibition of phosphodiesterase type-1-independent nuclear factor-κB signaling pathway and the release of inflammatory cytokines. In this study, we investigated the effect of vinpocetine on the proliferation of colon cancer cells and its underlying molecular mechanisms. Our data showed that vinpocetine inhibits the viability and proliferation of colon cancer cells. Vinpocetine treatment induced cell death in HCT116 cells, which the percentages of sub-G1 phase were significantly increased, and the apoptosis-related genes were regulated after HCT116 cells were treated with vinpocetine. In sum, our findings indicated that vinpocetine could be a therapeutically useful candidate in the treatment of colon cancer.

Keywords

References

  1. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 2004;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
  2. Zhang YS, Li JD, Yan C. An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol 2018;819: 30-4. doi: 10.1016/j.ejphar.2017.11.041.
  3. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 2011;63:618-28. doi: 10.1016/s1734-1140(11)70574-6.
  4. Dezsi L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm Hung 2002;72:84-91. Hungarian.
  5. Szilagyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Marian T, Molnar T, Szakall S, Tron L, Bereczki D, Csiba L, Fekete I, Kerenyi L, Galuska L, Varga J, Bonoczk P, Vas A, Gulyas B. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 2005;229-230:275-84. doi: 10.1016/j.jns.2004.11.053.
  6. Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 1984;33:453-7. doi: 10.1016/0006-2952(84)90240-5.
  7. Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996;24:129-34. doi: 10.1007/BF00304075.
  8. Bonoczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E, Kiss B, Kapas M, Szantay C, Koncz I, Zelles T, Vas A. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 2000;53:245-54. doi: 10.1016/s0361-9230(00)00354-3.
  9. Sitges M, Galvan E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 2005;46:533-40. doi: 10.1016/j.neuint.2005.02.001.
  10. Giachini FR, Lima VV, Carneiro FS, Tostes RC, Webb RC. Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension 2011;57:655-63. doi: 10.1161/HYPERTENSIONAHA.110.164327.
  11. Wu MP, Zhang YS, Xu X, Zhou Q, Li JD, Yan C. Vinpocetine attenuates pathological cardiac remodeling by inhibiting cardiac hypertrophy and fibrosis. Cardiovasc Drugs Ther 2017;31:157-66. doi: 10.1007/s10557-017-6719-0.
  12. Colombo BB, Fattori V, Guazelli CFS, Zaninelli TH, Carvalho TT, Ferraz CR, Bussmann AJC, Ruiz-Miyazawa KW, Baracat MM, Casagrande R, Verri WA Jr. Vinpocetine ameliorates acetic acid-induced colitis by inhibiting NF-κB activation in mice. Inflammation 2018;41:1276-89. doi: 10.1007/s10753-018-0776-9.
  13. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDEindependent mechanism. Proc Natl Acad Sci U S A 2010;107:9795-800. doi: 10.1073/pnas.0914414107.
  14. Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY, Tang YB. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis 2012;17:1120-30. doi: 10.1007/s10495-012-0743-0.
  15. Ahn HS, Crim W, Pitts B, Sybertz EJ. Calcium-calmodulinstimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprotein Res 1992;25:271-88.
  16. Kaneko S, Takahashi H, Satoh M. The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: effects of bifemelane and several nootropic agents. Eur J Pharmacol 1990;189:51-8. doi: 10.1016/0922-4106(90)90229-q.
  17. Erdo SA, Molnar P, Lakics V, Bence JZ, Tomoskozi Z. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. Eur J Pharmacol 1996;314:69-73. doi: 10.1016/s0014-2999(96)00542-0.
  18. Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov VA, Berk BC, Yan C. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 2006;98:777-84. doi: 10.1161/01.RES.0000215576.27615.fd.
  19. Dunkern TR, Hatzelmann A. Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 2007;274:4812-24. doi: 10.1111/j.1742-4658.2007.06001.x.
  20. Mehta A, Patel BM. Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors. Life Sci 2019;230:150-61. doi: 10.1016/j.lfs.2019.05.043.
  21. Sengupta R, Sun T, Warrington NM, Rubin JB. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 2011;32:337-44. doi: 10.1016/j.tips.2011.02.015.
  22. Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017;186:57-62. doi: 10.1007/s11845-016-1464-0.
  23. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40. doi: 10.1016/j.semcancer.2011.12.005.
  24. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23. doi: 10.1016/j.ccr.2005.04.014.
  25. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457:200-4. doi: 10.1038/nature07475.
  26. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-4. doi: 10.1038/nature05656.
  27. Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res 2015;21:527-34. doi: 10.1007/s12253-015-9913-z.
  28. Medina AE. Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A 2010;107:9921-2. doi: 10.1073/pnas.1005138107.
  29. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. doi: 10.1038/nature04870.
  30. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59. doi: 10.1038/nri1703.